Lausanne, Switzerland and Bad Homburg, Germany – Debiotech SA, a Swiss medical device developer with expertise in innovative technologies and miniaturized medical equipment and devices, and Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, have entered into an exclusive partnership to develop a portfolio of state-of-the-art peritoneal dialysis (PD) technologies. This partnership will bring Debiotech's specialized expertise to the dialysis industry.
The new product platform will offer dialysis machines that are lightweight and compact, making it more practical to dialyze at home. The smaller size of Fresenius Medical Care's new generation of PD machines will provide flexibility for dialysis patients when they travel, their intuitive design will promote ease of use, and their accompanying teaching methods are intended to make it easy for patients who are new to PD to use the machines.
Experts from both companies are working together to plan for multiple generations of innovations, offering more patients the option to dialyze at home than ever before.
"This agreement represents an ideal synergy to help patients everywhere who suffer from end stage renal disease receive the most appropriate treatment at home," said Dr. Frédéric Neftel, president and CEO of Debiotech. "We are very proud to work together with Fresenius Medical Care's outstanding teams in order to bring new home peritoneal dialysis products to market and offer the hope of improved quality of life for many patients around the world."
"We are dedicated to continuing to produce home dialysis machines that are as easy and convenient as possible for our customers to operate, because this is what they demand and deserve," said Mark Costanzo, President, Fresenius Medical Care Renal Therapies Group. "We expect that collaborating with such an exceptional team will provide dialysis patients with generations of products that will offer them a new level of ease of use and flexibility to help them meet their goal to dialyze at home."
The Fresenius Medical Care and Debiotech partnership is exclusive globally, with the exception of Japan.
Worldwide, more than 2.6 million patients with end stage renal disease regularly undergo dialysis treatment, a vital blood cleansing procedure that substitutes the function of the kidney.
Source: Debiotech & Fresenius Medical Care